Strata Oncology, Inc.
8170 Jackson Road, Suite A
Ann Arbor
Michigan
48103
United States
Tel: 734-527-1000
Website: http://www.strataoncology.com/
44 articles with Strata Oncology, Inc.
-
Strata Oncology Announces Publication of Study Validating Clinical Utility of Pan-tumor Predictive Biomarker for Checkpoint Inhibitor Immunotherapy Benefit
2/7/2023
Strata Oncology, Inc., a next-generation precision oncology company enabling smarter and earlier cancer treatment, today announced the publication of a new peer-reviewed study validating the clinical utility of the company's proprietary pan-solid tumor predictive biomarker for anti-PD-1/PD-L1 checkpoint inhibitor monotherapy benefit, Immunotherapy Response Score (IRS).
-
Strata Oncology Announces Addition of Gilead as Strata PATH Trial Collaborator
1/18/2023
Strata Oncology, Inc. today announced that Gilead Sciences, Inc. has agreed to collaborate on the Strata Precision Indications for Approved THerapies (Strata PATH™) trial by providing TRODELVY® (Sacituzumab govitecan-hziy) for eligible patients with cancer.
-
Strata Oncology Announces Expansion of Clinical Collaboration with Pfizer for Strata PATH Trial into Early-Stage Cancer
9/13/2022
Strata Oncology, Inc . a next-generation precision oncology company enabling smarter and earlier cancer treatment, today announced expansion of its clinical collaboration with Pfizer (NYSE: PFE) in the Strata Precision Indications for Approved THerapies (Strata PATHTM) trial.
-
Strata Oncology and University of Wisconsin Carbone Cancer Center Integrate StrataNGS® Test Results with Epic Genomics Module to Enhance Research and Workflows
9/7/2022
Strata Oncology, Inc. announced the integration of discrete genomic data from its StrataNGS® next-generation sequencing-based tumor profiling with the University of Wisconsin Carbone Cancer Center and UW Health Epic genomics module.
-
Strata Oncology Expands Strata PATH Trial to Eight Sarah Cannon Research Institute Sites
8/16/2022
Strata Oncology, Inc., a next-generation precision oncology company enabling smarter and earlier cancer treatment, today announced that Sarah Cannon Research Institute (SCRI) has joined the Strata Precision Indications for Approved THerapies (Strata PATH™) trial.
-
Strata Oncology Expands Sentinel Trial with Lehigh Valley Topper Cancer Institute and University of Michigan Health Rogel Cancer Center to Bring Precision Therapies to Patients Earlier in Their Cancer Journey
6/23/2022
100,000-patient prospective, observational study to evaluate ctDNA-based minimal residual disease (MRD) testing.
-
Strata Oncology Senior Vice President of Clinical Development Kat Kwiatkowski to Participate in Two Panels at Precision Medicine World Conference
6/16/2022
Strata Oncology, Inc. announced that its Senior Vice President of Clinical Development Kat Kwiatkowski, Ph.D., will participate in two panel discussions at the Precision Medicine World Conference 2022, being held live from June 28-30 in Santa Clara, CA.
-
Strata Oncology Expands Strata PATH Trial with Two New Partners
5/26/2022
Strata Oncology, Inc., a next-generation precision oncology company enabling smarter and earlier cancer treatment, today announced that two new health system partners.
-
Strata Oncology Enrolls First Patient in Strata PATH Trial Investigating New Pan-Tumor Indications for Approved Cancer Therapies
5/11/2022
Strata Oncology, Inc., a next-generation precision oncology company enabling smarter and earlier cancer treatment, today announced enrollment of the first patient in the Strata Precision Indications for Approved THerapies (Strata PATH™) trial, a prospective pan-tumor therapeutic trial designed to evaluate the efficacy and safety of multiple FDA-approved cancer therapies in new, biomarker-guided patient populations.
-
Strata Oncology Appoints Sundu Brahmasandra as Chief Operating Officer
3/22/2022
Strata Oncology, Inc., a precision oncology company advancing molecular indications for cancer therapies, announced the appointment of Sundu Brahmasandra as Chief Operating Officer.
-
Strata Oncology Sentinel Trial for Personalized Cancer Recurrence Monitoring Enrolls First Patient
3/16/2022
Strata Oncology, Inc., today announced enrollment of the first patient in the Strata Sentinel™ trial, a prospective, observational study that will evaluate the ability of the investigational StrataMRD™ test to detect cancer recurrence in advance of standard of care techniques across solid tumors.
-
Strata Oncology Named to Fast Company's Annual List of the World's 50 Most Innovative Companies for 2022
3/8/2022
Strata Oncology, a precision oncology company advancing new molecular indications for cancer therapies, has been named to Fast Company's prestigious annual list of the World's Most Innovative Companies for 2022.
-
Strata Oncology Appoints Jennifer Reyntjes as Chief People Officer
11/2/2021
Strata Oncology, Inc., a precision oncology company advancing molecular indications for cancer therapies, announced the appointment of Jennifer Reyntjes as Chief People Officer.
-
Strata Oncology Announces Publication of Analytical and Clinical Validation of StrataNGS® in the Journal of Molecular Diagnostics
9/8/2021
Strata Oncology, Inc today announced results from validation studies demonstrating the reliable performance of the StrataNGS test were published in The Journal of Molecular Diagnostics.
-
Show me the money! This week's who's who of IPOs and financing rounds in the biopharma world.
-
Three major pharmaceutical and biotechnology companies announce the success of their respective funding rounds to support future efforts.
-
Strata Oncology Completes $90 Million Series C Financing
7/28/2021
Strata Oncology, Inc., a precision oncology company advancing molecular indications for cancer therapies, announced the completion of a $90 million Series C financing, bringing the company's total financing to over $130 million since the company's inception.
-
Strata Oncology Presents Data at ASCO 2021 Showing Comprehensive Genomic and Transcriptomic Profiling Predicts Pan-Tumor Benefit of Pembrolizumab
6/4/2021
Strata Oncology ® , Inc ., a precision oncology company advancing molecular indications for cancer therapies, today announced the results of a study focused on evaluating a novel biomarker approach for immunotherapy
-
Strata Oncology Launches Strata Assistant Epic app to Integrate Precision Oncology into Clinical Practice
5/18/2021
Strata Oncology, Inc ., a precision oncology company advancing molecular indications for cancer therapies, today announced the launch of the Strata Assistant TM app for Epic with Kettering Health Network as its first fully integrated user.
-
Strata Oncology Announces Poster Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting
5/4/2021
Strata to present data on comprehensive genomic and transcriptomic profiling in patients with advanced solid tumors